Video

Dr. Saw Discusses Study of Vitamin D in Melanoma

Robyn Saw, FRACS, MS, MBBS, associate professor of surgery, The University of Sydney, discusses a study of vitamin D in melanoma.

Robyn Saw, FRACS, MS, MBBS, associate professor of surgery, The University of Sydney, discusses a study of vitamin D in melanoma.

This phase II study aims to find an alternative therapy option for patients with melanoma who are at high risk for recurrence. Currently, the only option for these patients is surgery.

In the study, patients received adjuvant therapy with high-dose vitamin D following primary treatment. Vitamin D has shown potential to delay recurrence and improve prognosis. Currently, there is no effective nontoxic adjuvant therapy for this population.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD